Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, PerkinElmer Ink Assay Development Deal Targeting Liver Cancer

NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into an R&D agreement with PerkinElmer Health Sciences to design an assay for evaluating a patient's risk of developing hepatocellular carcinoma.

The assay will be based on Trovagene's TrNA technology, the company said in a document filed with the US Securities and Exchange Commission, adding that both firms will jointly validate the assay and evaluate the possibility of combining the TrNA technology with PerkinElmer's technology for automation of nucleic acid isolation.

Trovagene's TrNA, or transrenal nucleic acid, testing technology is based on a method of nucleic acid isolation followed by the detection of specific genetic markers. The technology, according to the San Diego-based firm, can be used for a broad variety of medical conditions.

Under the terms of the deal, PerkinElmer will pay Trovagene milestone payments. PerkinElmer also has received an exclusive option to obtain a royalty-bearing license to use Trovagene's technology within the area of hepatocelluar carcinoma, as well as an exclusive option to obtain a royalty-bearing license to use Trovagene's technology in fields other than hepatocellular carcinoma.

Under certain conditions Trovagene has the option to obtain a royalty-bearing license to PerkinElmer's interest in any invention and/or intellectual property.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.